Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists

Pituitary

Volumn 10, Issue 1, 2007, Pages 81-86

  Neff, Lisa M ^a   Weil, Michelle ^a   Cole, Alan ^b   Hedges, Thomas R ^a   Shucart, William ^a   Lawrence, Donald ^a   Zhu, Jay Jiguang ^a   Tischler, Arthur S ^a   Lechan, Ronald M ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Dopamine agonist resistance; Prolactinoma; Temozolomide

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BROMOCRIPTINE; CABERGOLINE; DEXAMETHASONE; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; LETROZOLE; OCTREOTIDE; ONDANSETRON; PENTETREOTIDE; PENTETREOTIDE IN 111; PROLACTIN; RALOXIFENE; TEMOZOLOMIDE;

ADULT; AMENORRHEA; ARTICLE; BONE MARROW SUPPRESSION; CANCER INVASION; CASE REPORT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL FEATURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; MULTIPLE CYCLE TREATMENT; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; RADIATION DOSE; RADIOSURGERY; RETREATMENT; TRANSSPHENOIDAL SURGERY; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR RESISTANCE; UNSPECIFIED SIDE EFFECT;

DACARBAZINE; DOPAMINE AGONISTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA;

EID: 34147157741     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-007-0014-1     Document Type: Article

References (37)

1. Gillam M, Molitch M, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocrine Rev 27:485-534
2. Molitch M (2005) Pharmacologic resistance in prolactinoma patients. Pituitary 8:43-52
3. Saeger W, Farrell WE, Horvath E, Lloyd RV, Kovacs K, Watson RE Jr, Lindell EP (2004) Proloctin secreting adenoma. In: DeLellis R, Lloyd R, Heitz P (eds) WHO classification of tumours, pathology & genetics, tumours of endocrine organs. IARC Press, Lyon, pp 20-23
4. Riss D, Jin L, Qian X, Bayliss J, Scheithauer B, Young WJ, Vidal S, Kovacs K, Raz A, Lloyd R (2003) Differential expression of galectin-3 in pituitary tumors. Cancer Res 63:2251-2255
5. Zhu Y, Shahinian H, Bonert V, Lim S, Heaney A (2004) OR 43-5 Temodar: novel treatment for pituitary carcinoma. In The Endocrine Society Annual Meeting
6. Lim S, Shahinian H, Maya M, Yong W, Heaney A (2006) Temodar: Novel treatment for pituitary carcinoma. Lancet Oncol 7:518-520
7. Tsagarakis S, Grossman A, Plowman P, Jones A, Touzel R, Rees L, Wass J, Besser G (1991) Megavoltage pituitary irradiation in the management of prolactinomas: Long-term follow-up. Clin Endocrinol 34:399-406
8. Tsang R, Brierley J, Panzarella T, Gospodarowicz M, Sutcliffe S, Simpson W (1996) Role of radiation therapy in clinical hormonally-active pituitary adenomas. Radiother Oncol 41:45-53
9. Brada M, Ajithkumar T, Minniti G (2004) Radiosurgery for pituitary adenomas. Clin Endocrinol 61:531-543
10. Garcia M, Kapcala L (1995) Growth of a microprolactinoma to a macroprolactinoma during estrogen therapy. J Endocrinol Invest 18:450-455
11. Molitch M (2002) Medical management of prolactin-secreting pituitary adenomas. Pituitary 5:55-65
12. Bronstein MD (2005) Prolactinomas and pregnancy. Pituitary 8:31-38
13. Karumakaran S, Page R, Wass J (2001) The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin Endocrinol 54:295-300
14. Kaptain G, Simmons N, Alden T, Lopes M, Vance M, Laws E (1999) Estrogen receptors in prolactinomas: A clinico-pathological study. Pituitary 1:91-98
15. Lamberts S, Verleun T, Hofland L, Oosterom R (1986) Differences in the interaction between dopamine and estradiol on prolactin release by cultured normal and tumorous human pituitary cells. J Clin Endocrinol Metab 63:1342-1347
16. Volker W, Gehring W, Berning R, Schmidt R, Schneider J, von zur Muhlen A (1982) Impaired pituitary response to bromocriptine suppression: reversal after bromocriptine plus tamoxifen. Acta Endocrinol 101:491-500
17. Lamberts S, Verleun T, Oosterom R (1982) Effect of tamoxifen administration on prolactin release by invasive prolactin-secreting pituitary adenomas. Neuroendocrinol 34:339-342
18. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom H, Jaenicke F, Pluzanska A, Dank M, Becquart D, Bapsy P, Salminen E, Snyder R, Chaudri-Ross H, Lang R, Wyld P, Bhatnagar A (2004) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21:2101-2109
19. Thurlimann B, Keshaviah A, Coates A, Mouridsen H, Mauriac L, Forbes J, Paridaens R, Castiglione-Gertsch M, Gelber R, Rabaglio M, Smith I, Wardly A, Price K, Goldhirsch A (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New Engl J Med 353:2747-2757
20. Gilliam M, Middler S, Freed D, Molitch M (2002) The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. J Clin Endocrinol Metab 87:4447-4451
21. Freda P (2002) Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 87:3013-3018
22. Lamberts S, Zweens M, Klijn J, van Vroonhoven C, Stefanko S, Del Pozo E (1986) The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly. Clin Endocrinol 25:201-212
23. Jaquet P, Ouafik L, Saveanu A, Gunz G, Fina F, Dufour H, Culler M, Moreau J (1999) Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. J Clin Endocrinol Metab 84:3268-3276
24. Shimon I, Yan X, Taylor J, Weiss M, Culler M, Melmed S (1997) Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest 100:2386-2392
25. Hofland L, van der Hoek J, van Koetsveld P, de Herder W, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, Feelders R, van der Lely A, Beckers A, Lamberts S (2004) The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab 89:1577-1585
26. Grottoli S, Gasco V, Broglio F, Baldelli R, Ragazzoni F, Gallenca F, Mainolfi A, Prodam F, Muccioli G, Ghigo E (2006) Cortistatin-17 and somatostatin-14 display the same effects on growth hormone, prolactin, and insulin secretion in patients with acromegaly or prolactinoma. J Clin Endocrinol Metab 91:1595-1599
27. Rocheville M, Lange D, Kumar U, Patel S, Patel R, Patel Y (2000) Receptors for dopamine and somatostatin: Formation of hetero-oligomers with enhanced functional activity. Science 288:154-157
28. Seveanu A, Lavaque E, Gunz G, Barlier A, Kim S, Taylor J, Culler M, Enjalbert A, Jaquet P (2002) Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J Clin Endocrinol Metab 87:5545-5552
29. Kaltsas G, Mukherjee J, Plowman P, Monson J, Grossman A, Besser G (1998) The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. J Clin Endocrinol Metab 83:4233-4238
30. Hurel S, Harris P, McNicol A, Foster S, Kelly W, Baylis P (1997) Metastatic prolactinoma: Effect of octreotide, cabergoline, carboplatin, and etoposide: Immunocytochemical analysis of proto-oncogene expression. J Clin Endocrinol Metab 82:2962-2965
31. Kulke M, Stuart K, Enzinger P, Ryan D, Clark J, Muzikansky A, Vincitore M, Michelini A, Fuchs C (2006) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24:401-406
32. Bafaloukos D, Tsoutsos D, Kalofonos H, Chalkidou S, Panagiotou P, Linardou E, Briassoulis E, Efstathiou E, Polyzos A, Fountzilas G, Christodoulou C, Kouroussis C, Iconomou T, Gogas H (2005) Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: A randomized phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 16:950-957
33. Nagasubramanian R, Dolan M (2003) Temozolomide: Realizing the promise and potential. Curr Opin Oncol 15:412-418
34. Hegi M, Diserens A, Godard S, Dietrich P, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N, Stupp R (2004) Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10:1871-1874
35. 6-methylguanine. Oncogene (advance online publication). doi:10.1038/sj.onc.1209785
36. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793-797
37. Hegi M, Diserens A, Gorlia T, Hamou M, de Tribolet N, Weller M, Kros J, Hainfellner J, Mason W, Mariani L, Bromberg J, Hau P, Mirimanoff R, Cairncross J, Janzer R, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003